113 related articles for article (PubMed ID: 30604736)
1. Cetuximab in combination with chemoradiotherapy for nasopharyngeal carcinoma: A meta-analysis.
Wang N; Wang K; Song F; Liu Y
Indian J Cancer; 2018; 55(2):196-200. PubMed ID: 30604736
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R; Hua YJ; Liu YP; Yang Q; Zhang YN; Li JB; Li CF; Zou X; Yu T; Cao JY; Zhang MX; Jiang R; Sun R; Mo HY; Guo L; Cao KJ; Lin AH; Sun Y; Qian CN; Ma J; Chen MY
Theranostics; 2017; 7(8):2314-2324. PubMed ID: 28740554
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
5. Effect of cetuximab combined with IMRT and concurrent chemotherapy in treating locally advanced nasopharyngeal carcinoma.
Yang P; Liu J; Yong H; Ma J; Gao X
J BUON; 2021; 26(1):138-144. PubMed ID: 33721444
[TBL] [Abstract][Full Text] [Related]
6. Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: A propensity score analysis.
Xia WX; Liang H; Lv X; Wang L; Qian CN; Ye YF; Ke LR; Qiu WZ; Yu YH; Huang XJ; Liu GY; Zhao C; Xiang YQ; Guo X
Oral Oncol; 2017 Apr; 67():167-174. PubMed ID: 28351572
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma: A network meta-analysis.
Yuan C; Xu XH; Xu L; Liu Y; Sun M; Ni LH; Wang XL; Chen Z; Zhang K; Wan HL; Zeng G
J BUON; 2017; 22(4):1004-1010. PubMed ID: 28952220
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials.
Huang ZH; Ma XW; Zhang J; Li X; Lai NL; Zhang SX
BMC Cancer; 2018 Nov; 18(1):1170. PubMed ID: 30477458
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of induction chemotherapy in treatment for locally advanced nasopharyngeal carcinoma--A time-to-event meta-analysis.
Song Y; Wang W; Tao G; Zhou X
Oral Oncol; 2015 Aug; 51(8):764-9. PubMed ID: 26050095
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment.
Chen X; Hong Y; Feng J; Ye J; Zheng P; Guan X; You X; Song H
Chin Med J (Engl); 2014; 127(1):142-9. PubMed ID: 24384440
[TBL] [Abstract][Full Text] [Related]
12. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
[TBL] [Abstract][Full Text] [Related]
13. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
15. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Jing W; Yan W; Liu Y; Li J; Yu J; Zhu H
Cancer Biol Ther; 2019; 20(8):1121-1126. PubMed ID: 30983494
[TBL] [Abstract][Full Text] [Related]
16. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
[TBL] [Abstract][Full Text] [Related]
17. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Cetuximab in Nasopharyngeal Carcinoma Patients Receiving Concurrent Cisplatin-Radiotherapy: A Meta-Analysis.
Wang L; Liu D; Wei D
Comput Math Methods Med; 2022; 2022():5145549. PubMed ID: 36060662
[TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
20. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
Wang C; Tang X; Wang J; Song J; Xu Y
Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
